Dr. Shane Dormady 醫學博士兼哲學博士，現任 El Camino Health 腫瘤科 Ocampo Family Medical Director，分享液體活檢如何協助偵測具治療意義的基因突變，支持轉移性乳癌的個人化治療策略，並透過精準標靶治療改善病人的治療成效。 Lucence 的 LiquidHALLMARK® 是一項高靈敏度液體活檢檢測，透過分析ctDNA與ctRNA，協助制定個人化治療方案。請諮詢您的醫療機構，以獲取有關您的醫療方案的建議。

Lucence 的液體活檢產品並非作為伴隨診斷工具而設計或指定使用，亦非旨在取代醫師的臨床判斷，且並非用於診斷特定病症或疾病，亦非用於為特定病症或疾病確定適當的治療方案。

Shane 醫師所發表的言論僅代表其個人專業見解，未必代表 Lucence 作為組織的觀點。Shane 醫師是 Lucence 的受聘顧問。

影片字稿： I am Dr. Shane Dormady, MD, PhD. I'm the Ocampo Family Medical Director of Oncology at El Camino Health. My inspiration to be an oncologist was really to try to take a very terrifying diagnosis and turn that from doom and gloom into inspiration and hope. And one of the amazing tools that helps me do that in this day and age is really analyzing the DNA of a person's cancer cells and thereby personalizing their treatment.

I met a patient in her 50s. She was diagnosed with widely metastatic breast cancer. She did have stable disease for approximately two years, but then she presented rather dramatically and suddenly with vision changes in her left eye, and MRI imaging revealed a new mass in her orbit. Restaging CT scans at that time showed that she had rather rapidly developed innumerable disseminated bilateral pulmonary metastases.

It is my practice whenever we see progression of a metastatic cancer to resend a liquid biopsy. What we found compared to our original molecular profiling was the presence of a PIK3CA mutation, which is readily targetable with multiple medications. So we changed her therapy to incorporate a PIK3CA inhibitor and changed her anti-estrogen therapy. And within six months, the innumerable pulmonary metastases had completely resolved. In addition, there was a regression of the mass in the orbit, and her vision normalized.

As patients get more frail with third and fourth and fifth lines of treatment, sometimes it's very difficult to send them for invasive biopsies and surgeries of tumor masses within the body. It's analysis of that sort of genetic material from the tumor cells that can lead to breakthroughs for the patient's treatment, because as we all know, our newer targeted therapies tend to have fewer side effects than the toxic infusions of chemotherapy and even immunotherapy.